Improved antigen cross-presentation by polyethyleneimine-based nanoparticles by Chen, Jian et al.
© 2011 Chen et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2011:6 77–84
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
77
OrIgINAL reseArCh
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/IJN.S15457
Improved antigen cross-presentation  
by polyethyleneimine-based nanoparticles
Jian Chen1
Zhengrong Li1
hong huang2
Yanzhu Yang2
Qian Ding2
Junhua Mai1
Wei guo2
Yuhong Xu2
1school of Life sciences and 
Biotechnology, 2school of Pharmacy, 
shanghai Jiao Tong University, 
shanghai, People’s republic of China
Correspondence: Yuhong Xu
school of Pharmacy, shanghai Jiao 
Tong University, shanghai,  
People’s republic of China
Tel +86 213 420 4739
Fax +86 213 420 4739
email yhxu@sjtu.edu.cn
Purpose: In the development of therapeutic vaccines against cancer, it is important to design 
strategies for antigen cross-presentation to stimulate cell-mediated immune responses against 
tumor antigens.
Methods: We developed a polyethyleneimine (PEI)-based protein antigen delivery system to 
promote cross-presentation through the major histocompatibility complex (MHC) I pathway 
using ovalbumin (OVA) as a model antigen. PEIs formed nanoparticles with OVA by electro-
static interactions, as demonstrated by electrophoresis analysis, scanning electron microscopy, 
and photon correlation spectroscopy analysis.
Results: The nanoparticles were used to stimulate mouse bone marrow-derived dendritic cells 
in vitro and resulted in significantly more OVA257–264/MHC I complex presentation on dendritic 
cell surfaces. The activated dendritic cells interacted specifically with RF33.70 to stimulate 
interleukin-2 secretion. The cross-presentation promoting effect was more prominent in dendritic 
cells that had been cultured for longer periods of time (13 days). Further studies comparing the 
antigen presentation efficacies by other polyanionic agents, such as PLL or lysosomotropic 
agents, suggested that the unique “proton sponge effect” of PEI facilitated antigen escape from 
the endosome toward the MHC I pathway.
Conclusion: Such a PEI-based nanoparticle system may have the potential to be developed 
into an effective therapeutic vaccine delivery system.
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Introduction
Cancer vaccines are viewed as promising tools to fight tumors.1,2 The aim of a cancer 
vaccine is to activate the patient’s own immune system against tumor cells. There have 
been many cancer vaccine strategies proposed and tested, including tumor cell lysates, 
tumor antigen-pulsed dendritic cells, recombinant tumor antigens, and various DNA 
vaccine constructs.3,4 However, the outcomes are highly variable and there have been 
safety and quality control problems. Based on these concerns, vaccine constructs 
containing recombinant tumor-associated antigens or epitopes are considered more 
desirable because of the advantages of easy production, convenient administration, 
and proven safety.5
Protein-based cancer vaccines in general have limited therapeutic efficacy because 
they induce predominantly antibody responses instead of antigen-specific cytotoxic T 
lymphocyte responses, which are critical for immunity against tumors.6 Controlling 
the antigen-processing process inside antigen-presenting cells and presenting 
them through the major histocompatibility complex (MHC) I pathway is the key to International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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  stimulating cytotoxic T lymphocytes.7,8 Nanoparticle-based 
delivery   systems have shown some efficacy in protecting 
antigens from degradation and improving uptake by antigen-
presenting cells.9 In order to help the antigens to escape from 
endosomes inside antigen-presenting cells and to access the 
MHC I pathway, some endosome-disruptive agents were 
applied. Based on the listeriolysin O protein, Stier et al 
designed a listeriolysin O-liposome system that could cre-
ate pores within the endosomal/lysosomal membrane.10 
  Bungener et al used reconstituted virosomes from the influ-
enza virus and reported membrane fusion between the viro-
some membrane and the endosome membrane.11 Kwon et al 
and Murthy et al prepared a responsive polymer microsphere 
that degraded in the acidic lysosome to release the antigen.12,13 
Antigen cross-presentation was considered essential for the 
efficacy of therapeutic vaccines.
In this study we developed a new antigen delivery system 
based on the cationic polymer polyethyleneimine (PEI) and 
demonstrated that its endosome-disruptive effect was suffi-
cient and effective for cross-presentation. Ovalbumin (OVA) 
was used as a model antigen, and various aspects of immune 
recognition and stimulation were demonstrated. Mouse bone 
marrow-derived dendritic cells were used to evaluate cross-
presentation efficiency, because dendritic cells were viewed 
as the most powerful antigen-presenting cells.14,15 Our study 
indicates that the PEI-based nanoparticles show promise as 
antigen delivery systems for therapeutic cancer vaccines.
Materials and methods
Materials
OVA 257–264 peptide was synthesized by GL Biochem Ltd, 
Shanghai, China. OVA and PEI (branched, 10 kDa) were 
purchased from Sigma-Aldrich, St Louis, MO, USA. Goat 
antimouse IgG–FITC was purchased from the KangChen 
Bio-tech Company, Shanghai, China. Mouse granulocyte–
macrophage colony-stimulating factor and mouse 
  interleukin (IL)-4 were purchased from R & D Systems, 
Minneapolis, MN, USA. Cell culture media were obtained 
from Gibco Invitrogen, Carlsbad, CA, USA.
RF33.70 cells (Kb restricted T cell hybridoma and specific 
for OVA257–264) were kindly provided by Professor Xuetao 
Cao from the Second Military Medical University, Shanghai, 
China. These cells were maintained in RPMI-1640 culture 
medium with 10% heat-inactivated fetal bovine serum and 
antibiotics.
The hybridoma cells that produced the monoclonal anti-
body 25-D1.16, specific for the OVA257–264/MHC I complex, 
were kindly provided by Professor Kyung-Dall Lee from the 
University of Michigan, Ann Arbor, MI, USA. The cell line 
was grown in RPMI-1640 with 10% fetal bovine serum.
Five- to six-week-old male C57BL/6 mice (H-2b) were 
purchased from the Shanghai Laboratory Animal Center, 
Shanghai, China, and were housed in a specific pathogen-free 
environment at Shanghai Jiao Tong University School of 
Pharmacy. All experiments were approved by the Animal 
Care and Use Committee of Shanghai Jiao Tong University 
School of Pharmacy, Shanghai, China.
The bone marrow-derived dendritic cells were prepared 
based on the typical procedure described in the literature.16 
Briefly, bone marrow from C57BL/6 mice was collected 
and cultured in RPMI-1640 complete medium (10% heat-
inactivated fetal bovine serum, 100 U/mL penicillin, 
100 U/mL streptomycin) supplemented with 10 ng/mL mouse 
granulocyte–macrophage colony-stimulating factor and 
1 ng/mL mouse IL-4. Nonadherent cells were removed after 
three days, and the adherent cells were replanted in fresh 
RPMI-1640 complete medium supplemented with mouse 
granulocyte–macrophage colony-stimulating factor and IL-4. 
The nonadherent and loosely adherent cells were harvested 
as dendritic cells after another three days.
Preparation of PeI–OVA  
and PLL–OVA nanoparticles
The nanoparticles were prepared following the protocols 
that were used to prepare polymer–DNA complex with 
modification.17,18 OVA was dissolved in 1 mM HEPES 
(pH 7.4) solution to get an OVA concentration of 5 mg/mL. 
Branched PEI10000 (Sigma) or PLL26000 (Sigma) was dissolved 
in distilled water to yield different concentration. Polymer–
OVA particles were prepared by adding OVA solution to 
polymer solution at equal volume and vortexing for 30   seconds 
at room temperature.
Nanoparticle characterization
The polymer–OVA nanoparticles were analyzed using both 
native sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (PAGE, 8%–16% Tris-Glycine gel) and denatured 
sodium dodecyl sulfate PAGE (4%–12% Bis-Tris gel 
from Invitrogen). Gels were stained with Coomassie Blue 
(Invitrogen).
The surface morphology of nanoparticles was observed 
by scanning electron microscopy (SEM, FEI SIRION 
200 system, FEI Company). After the samples were deposited 
on silica wafers and dried, they were observed at 5 kV. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The size distribution and zeta potential of the nanoparticles 
were determined using photon correlation spectroscopy 
(Zetasizer Nano ZS90, Malvern Corp, Malvern, UK) at a 
scattering angle of 90°C and a temperature of 25°C.
OVA257–264/MhC I complex 
characterization on dendritic cells
Polymer–OVA nanoparticles were added to dendritic cells at 
different concentrations. Dendritic cells were incubated overnight 
at 37°C and then harvested and washed with phosphate-buffered 
saline. The expression of OVA257–264/MHC I on the surface of 
the dendritic cells was determined by staining the cells with 
25-D1.16 monoclonal antibodies at 4°C. Thirty   minutes later, 
the dendritic cells were washed and incubated with secondary 
antibody for a further 30   minutes. The dendritic cells were then 
washed again and analyzed by flow cytometry.
IL-2 secretion by OVA257–264/MhC I 
complex-specific T cells
After addition of polymer–OVA nanoparticles, dendritic cells 
were harvested after 12 hours and diluted by RPMI-1640 
complete medium. 2 × 104 dendritic cells and 2 × 105 
RF33.70 cells per well were mixed and incubated in 96-well 
plates. After 24 hours of incubation, IL-2 concentration in 
the culture supernatant was determined by mouse IL-2 
enzyme-linked immunosorbent assay (ELISA) kit (Bender 
MedSystems, Austria).
Results
Preparation and characterization  
of PeI–OVA particles
We prepared PEI–OVA nanoparticles based on electrostatic 
interactions between the positive amino groups on PEI and the 
negative surface charges on OVA above its pKa. The two agents 
were mixed in different weight ratios, and the resulting com-
plexes were examined by gel electrophoresis. Figure 1A shows 
the native gel electrophoresis analysis of the complexes, which 
indicates that OVA was completely combined with PEI when 
the PEI/OVA weight ratio was over 0.04. However, the sodium 
dodecyl sulfate PAGE analysis showed that free OVA still 
existed at the same weight ratio   (Figure 1B). This phenomenon 
demonstrated that sodium dodecyl sulfate could compete with 
OVA and disturb the combination of PEI and OVA.
The microscopic morphology of the resulting particles 
was examined by SEM. The PEI–OVA nanoparticles were, 
in general, spherical and polydispersed. The SEM image of 
PEI–OVA 0.04 nanoparticles is shown in Figure 2A.
The particles were further evaluated by measuring their size 
distributions and surface zeta potential. As shown in Table 1, 
the zeta potentials of the particles increased with increasing 
ratios of PEI to OVA. The particles were positive when the 
PEI/OVA ratios were over 0.12. Table 1 also shows the average 
sizes of these particles, which were around several hundred 
nanometers between PEI/OVA ratios of 0.01 to 0.16.
For comparison, we also prepared different polycation–
antigen nanoparticles. PLL is another kind of widely used 
cationic polymer in gene transfection.19–21 PLL could form 
nanoparticles with OVA by electronic interaction. The zeta 
potential and size distribution were also determined by pho-
ton correlation spectroscopy. The results were similar to 
those we obtained from PEI–OVA nanoparticles (Table 2). 
SEM results also showed that the surface morphology looks 
similar (Figure 2B).
Improved OVA257–264/MhC I complex 
presentation on dendritic cells
OVA antigen processing and epitope loading by dendritic 
cells after interacting with the PEI–OVA nanoparticles were 
A
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Figure 1 Combination of PeI and OVA. A) Native gel electrophoresis of PeI–OVA 
particles in different ratios (PeI/OVA w/w). Lane 1, protein marker; Lane 2, OVA; 
Lane 3, 0.01; Lane 4, 0.02; Lane 5, 0.04; Lane 6, 0.06; Lane 7, 0.08; Lane 8, 0.12; Lane 9, 
0.16. B) sDs–PAge of PeI–OVA particles in different weight ratios. Lane 1, protein 
marker; Lane 2, OVA; Lane 3, 0.01; Lane 4, 0.02; Lane 5, 0.04; Lane 6, 0.06; Lane 7, 0.08; 
Lane 8, 0.12; Lane 9, 0.16.
Abbreviations:  PeI,  polyethyleneimine;  OVA,  ovalbumin;  sDs–PAge,  sodium 
dodecyl sulfate polyacrylamide gel electrophoresis.
Figure 2 seM image of A) PeI–OVA and B) PLL–OVA particles on silicon wafer.
Abbreviations: PLL, polylysine; PeI, polyethyleneimine; OVA, ovalbumin; seM, scan-
ning electromicroscopy.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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examined by determining the expression of OVA257–264/MHC I 
complexes on dendritic cell surfaces using the specific anti-
body 25-D1.16 monoclonal antibodies.22 No surface 
OVA 257–264/MHC I complexes were detected by the 25-D1.16 
monoclonal antibodies on naïve dendritic cells. Pulsing the 
dendritic cells with OVA antigen alone would generally result 
in antigen processing inside the endosome/lysosome and 
presentation through the MHC I pathway. Therefore, the 
OVA 257–264/MHC I complex signal was very low. Pulsing 
with PEI–OVA nanoparticles resulted in antigen release 
from endosomes and cross-presentation through the MHC I 
  pathway. Figure 3A shows the dendritic cell surface 
 OVA 257–264/MHC I signals after pulsing with PEI–OVA 
nanoparticles at different ratios. The PEI–OVA nanoparticle 
group that was prepared in a weight ratio of 0.04 had the 
highest mean signal intensity, approximately eight times 
higher than that of the OVA group.
The dendritic cell surface OVA257–264/MHC I signals after 
pulsing with PLL–OVA nanoparticles at different ratios 
showed a similar trend. The highest signal intensity was 
obtained at a weight ratio of 0.08 (Figure 3B).
IL-2 secretion by early and late  
dendritic cells after PeI–OVA pulsing
PEI–OVA pulsed dendritic cells were then incubated with a 
murine T cell hybridoma specific for OVA257–264 (RF33.70), 
and the resulting IL-2 concentration in the supernatant was 
measured as an indicator of the T cell stimulation effect of 
dendritic cells. Only those dendritic cells that contained 
antigens cross-presented by MHC I complexes interacted 
specifically with these T cells and upregulated IL-2 secretion. 
Two types of pulsed dendritic cells were examined. Bone 
marrow-derived dendritic cells that were harvested at day 6 
were designated as early dendritic cells, whereas the cells 
harvested at day 13 were designated as late dendritic cells.11 
In both cases, dendritic cells pulsed by the PEI–OVA 0.04 
nanoparticles showed a significantly improved T cell 
  stimulation effect compared with dendritic cells pulsed by 
OVA solution at the same concentration (Figure 4). We can 
see that the increasing extent was more obvious in late 
  dendritic cells, although the value was larger in early den-
dritic cells.
IL-2 secretion by dendritic cells  
after PLL–OVA pulsing
In contrast, as shown in Figure 5, there was no detectable 
increase observed in IL-2 secretion when RF33.70 cells were 
coincubated with dendritic cells pulsed by PLL–OVA nano-
particles prepared at all weight ratios. This indicated that 
PLL–OVA nanoparticles could not improve antigen cross-
presentation or stimulate antigen-specific T cells.
effect of chloroquine and Nh4Cl  
on OVA processing and cross-
presentation
Because compounds such as chloroquine and NH4Cl had 
been reported to be able to buffer and delay acidification of 
endosomes and lysosomes, the intracellular fate of exogenous 
antigens may be changed by addition of these compounds. 
To study the mechanism of antigen processing, we tested 
their effects on the outcome of antigen processing and pre-
sentation after PEI–OVA pulsing. As shown in Figure 6, 
these two compounds hindered the cross-presentation effi-
ciency of dendritic cells, which resulted in decreased IL-2 
expression following incubation with RF33.70 cells, as 
compared with the effect when the endosomes/lysosomes 
had a normal acidification process.
Discussion
The intracellular fate of antigens is pivotal to the immune 
effect. Exogenous antigens are usually degraded by enzymes 
in acidic endosomes, which causes failure to induce the 
cytotoxic T lymphocyte response. This is one of the main 
difficulties in the development of therapeutic cancer vaccines. 
As discussed earlier, methods have been developed to assist 
antigen escape and showed improved cross-presentation. The 
aim of our research was to provide a new strategy for antigen 
delivery.
Table 1 Average size and zeta potential of PeI–OVA particles 
were varied when mixed in different ratios
PeI/OVA  
weight ratio
0.01 0.02 0.04 0.06 0.08 0.12 0.16
Average size (nm) 69.4 104.4 169.0 342.7 359.7 262.0 297.5
Zeta potential (mV) −23.1 −20.3 −12.4 −4.6 −4.4 12.4 20.0
Abbreviations: PeI, polyethyleneimine; OVA, ovalbumin.
Table 2 Average size and zeta potential of PLL–OVA particles 
were varied when mixed in different ratios
PLL/OVA  
weight ratio
0.01 0.02 0.04 0.06 0.08 0.12 0.16
Average size (nm) 51.8 109.7 172.8 124.4 92.4 82.4 80.8
Zeta potential (mV) −18.4 −17.6 −5.8 32.9 35.6 43.5 47.7
Abbreviations: PLL, polylysine; OVA, ovalbumin.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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We prepared PEI–OVA nanoparticles by mixing PEI 
solution and OVA solution together. The nanoparticles 
interacted due to electrostatic interactions between the cat-
ionic polymer–PEI and the negatively charged protein–OVA. 
The electrostatic complexation process was confirmed by 
electrophoresis, SEM, zeta potential, and particle size 
  analysis. The nanoparticles formed were quite stable and 
their electrophoretic profiles, zeta potential, and size distribu-
tion data remained the same for several days. Stability is 
important in the potential application of these nanoparticles 
as therapeutic vaccine carriers.
The OVA257–264 peptide is a class I (Kb)-restricted peptide 
epitope of OVA that is presented by the MHC I complex on 
antigen-presenting cells. We measured the amount of 
OVA 257–264/MHC I complexes on dendritic cell surfaces as 
an indicator of the efficiency of antigen cross-presentation 
after OVA antigen pulsing. The 25-D1.16 antibody specifi-
cally recognizes OVA257–264/MHC I complexes.23 Our data 
indicated that the expression of OVA257–264/MHC I increased 
significantly after pulsing with PEI–OVA nanoparticles 
overnight. The extent of this increment was also found to 
be  related  to  the  PEI–OVA  mixing  weight  ratio. 
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Figure 4 Improved cross-presentation efficiency on early dendritic cells and late dendritic cells. Interleukin-2 concentration in supernatant was measured by ELISA when 
rF33.70 cells were coincubated for 24 hours with dendritic cells harvested at six days A) or dendritic cells harvested at 13 days, B) pulsed with PeI–OVA nanoparticles. Data 
are presented as mean ± sD, n = 4, **P , 0.01 versus OVA solution group.
Abbreviations: eLIsA, enzyme-linked immunosorbent assay; PeI, polyethyleneimine; OVA, ovalbumin.
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Figure 3 Quantification of dendritic cell surface OVA257–264/MhC I complexes. A) OVA257–264/MhC I complexes on the surface of dendritic cells after pulsing with PeI–OVA 
nanoparticles which were made using different ratios of PeI and OVA. Data are presented as mean ± standard deviation, n = 3. B) OVA257–264/MhC I complexes on the surface 
of dendritic cells after pulsing with PLL–OVA nanoparticles which were made using different ratios of PLL and OVA. Data are presented as mean ± standard deviation, n = 3, 
*P , 0.05 versus OVA solution group, **P , 0.01 versus control group. 
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The   nanoparticles with best immune effect were prepared 
at a weight ratio of 0.04. The cross-presentation effect was 
further   confirmed by IL-2 secretion of RF33.70 cells that 
were OVA257–264/MHC I-specific hybridoma cells. The den-
dritic cells pulsed by PEI–OVA nanoparticles at a weight 
ratio of 0.04 stimulated the most significant IL-2 secretion 
by RF33.70 cells. Other PEI–OVA ratio particles had very 
little effect. We suspect this may be because PEI had some 
cytotoxicity, which   interfered with the interaction between 
dendritic cells and RF33.70 cells. If a less toxic cationic 
polymer can be developed with similar functions, we may 
see greater   improvements in antigen processing and 
cross-presentation efficiencies.
On the contrary, the cross-presentation effect of the 
PLL–OVA nanoparticles was somewhat different. We did 
observe a significant OVA257–264/MHC I signal increase with 
25-D1.16 antibody staining, but there was no stimulation of 
IL-2   secretion by RF33.70 cells. The highest 25-D1.16 anti-
body staining signal was observed at a PLL to OVA weight 
ratio of 0.08 and above. Those nanoparticles had quite high 
positive surface charges, which may attract nonspecific bind-
ing of 25-D1.16 antibodies, resulting in false signal increase. 
  However, because the PLL–OVA pulsed dendritic cells had 
no effect on stimulating IL-2 secretion by RF33.70 cells, we 
concluded that PLL–OVA nanoparticles were not capable 
of promoting antigen cross-presentation in dendritic cells.
To understand the mechanism of PEI-mediated antigen 
cross-presentation, Yang and Hsu, and Yan et al proposed that 
it may be due to the positive surface charge that promoted 
uptake by dendritic cells and promoted the production of 
reactive oxygen species. The main evidence was the increased 
expression of CD80/CD86 on dendritic cell surfaces.24,25 
However, our findings were different. The PEI–OVA 0.04 
nanoparticles had a negative surface potential, and there was 
no significant upregulation of CD80/86 expression on den-
dritic cells. However, the improvement of specific OVA257–264/
MHC I presentation and functional stimulation of IL-2   secretion 
was significant. We believe that the PEI–OVA nanoparticles 
we prepared may be effective as a result of the special 
endosome-disruptive effect of PEI.
PEI is well known for its proton sponge effect, whereby 
the unprotonated amines of PEI can buffer influent protons, 
leading to osmotic swelling and rupture of endosomes.26 Such 
an endosomal rupturing effect may help antigen release from 
the endosome and its subsequent cross- presentation by the 
MHC I pathway. To find support for such a hypothesis, we 
further examined the effect of endosomal pH on cross- 
presentation efficiency. We made an interesting observation 
that the PEI effect on cross-  presentation with dendritic cells 
harvested at 13 days was more prominent than that with 
dendritic cells harvested at six days. This may be due to the 
different endosome acidification characteristics in dendritic 
cells harvested at six days versus dendritic cells harvested at 
13 days. Endosomal acidification was believed to control 
exogenous antigen degradation by influencing the activity 
of lysosomal proteases.27 Hotta et al reported that late 
  dendritic cells were usually not capable of cross-presenting 
exogenous antigens because the endocytic compartments 
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would acidify rapidly in late dendritic cells after antigen 
uptake, whereas in early dendritic cells the pH would be 
maintained at a mildly acidic level and allow some antigen 
escape from endosomes for cross-presentation.28 Therefore, 
our data suggest that PEI can buffer the influent protons in 
late dendritic cells and prevent rapid acidification, which 
resulted in greatly improved cross-presentation efficiency in 
dendritic cells harvested at 13 days.
We also examined the effects of two other lysosomotro-
pic agents, chloroquine and NH4Cl, on cross-presentation 
  efficiency. Both chloroquine and NH4Cl inhibit acidification 
of endosomes and have been reported to increase cross-
presentation of exogenous antigens.29–31 However, treatment 
with chloroquine or NH4Cl actually reduced PEI–OVA 
nanoparticle-mediated cross-presentation   (Figure 6). We 
think this is because the inhibition of endosome acidification 
by chloroquine and NH4Cl reduced the proton influx and 
prevented endosome rupture and antigen escape. This is 
consistent with a previous report that the use of chloroquine 
slightly decreased the gene transfection activity of PEI.17
Conclusion
In summary, our data demonstrate that PEI–OVA nanopar-
ticles were formed by electronic interactions, and the proton 
sponge effect of PEI was essential for promoting antigen 
cross-  presentation for therapeutic vaccine application. This 
system is attractive due to its simplicity, flexibility, stability, 
and high loading efficiency. The main limitation is the   toxicity 
of PEI.32 Further studies are needed to synthesize new poly-
mers that have the proton sponge effect but lower toxicity. 
Additionally, a targeting strategy may be necessary for in vivo 
applications.33
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